Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...

More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.

The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain to support the launch of its obesity pill orforglipron.

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for ...

The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...

The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...

The Kanakee project builds on the company’s efforts to increase its U.S. footprint, where it has already spent more than $3 ...

Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many ...

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...